Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PURINETHOL vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Acute lymphoblastic leukemia (ALL) maintenance therapy (FDA-approved),Chronic myeloid leukemia (CML) (off-label),Inflammatory bowel disease (Crohn's disease, ulcerative colitis) (off-label),Autoimmune hepatitis (off-label)
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Primarily metabolized by xanthine oxidase (XO) to 6-thiouric acid (inactive), and via thiopurine methyltransferase (TPMT) to 6-methylmercaptopurine (inactive). Activity of TPMT and NUDT15 affects toxicity. Allopurinol inhibits XO, leading to increased mercaptopurine levels.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 19% bound to plasma proteins, primarily albumin.
Approximately 20–30% bound to plasma proteins.
Volume of distribution is 0.9 L/kg, indicating distribution into total body water.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Oral bioavailability is highly variable, ranging from 5% to 37% (mean approximately 16%), due to extensive first-pass metabolism.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
GFR 50-80 m L/min: reduce dose by 25-50%. GFR 10-50 m L/min: reduce dose by 50-75%. GFR <10 m L/min: administer 50% of normal dose every 48 hours or consider alternative.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Induction: 50-75 mg/m² orally once daily. Maintenance: 50-75 mg/m² orally once daily. Adjust based on tolerance and disease response.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
Start at lower end of dosing range (1.5 mg/kg/day). Monitor renal function and hematologic parameters closely. Reduce dose if significant renal impairment present.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
Severe myelosuppression, especially with TPMT or NUDT15 deficiency. The drug is myelotoxic; fatal myelosuppression can occur. Monitor blood counts frequently.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Myelosuppression: monitor CBCs regularly; reduce dose if severe.,TPMT/NUDT15 deficiency: increased risk of severe myelosuppression; consider testing before therapy.,Hepatotoxicity: monitor liver function tests; can cause hepatic veno-occlusive disease.,Immunosuppression: increased risk of infections.,Carcinogenicity: risk of secondary malignancies, especially with prolonged use.,Pregnancy: Category D; may cause fetal harm.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to mercaptopurine,Prior resistance to mercaptopurine (ineffective),Severe myelosuppression (unless benefits outweigh risks),Concomitant use with allopurinol (unless dose-adjusted due to toxicity risk),Pregnancy (absolute contraindication in some contexts)
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Avoid grapefruit and grapefruit juice as they may increase drug levels. May decrease the effectiveness of warfarin; monitor INR if consuming vitamin K-rich foods. Alcohol consumption should be minimized due to potential hepatotoxicity.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intrauterine growth restriction, preterm delivery, and fetal myelosuppression. Overall, considered teratogenic in humans; avoid use unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Present in breast milk in low concentrations. M/P ratio not established. Potential for infant myelosuppression and immunosuppression. Contraindicated in breastfeeding or use with caution; monitor infant for neutropenia and thrombocytopenia.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
Increased clearance during pregnancy may require dose adjustment. Monitor therapeutic drug levels (if available) and clinical response. Dose may need to be increased by up to 50% in second and third trimesters; post-partum reduce dose to pre-pregnancy levels.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Purinethol (6-mercaptopurine) is a prodrug converted to active thioguanine nucleotides. Co-administration with allopurinol requires a 65-75% dose reduction of Purinethol due to inhibition of xanthine oxidase. TPMT genotyping or phenotyping is recommended prior to initiation to avoid severe myelosuppression. Monitor CBC and liver enzymes regularly. Avoid live vaccines during therapy.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Take this medication exactly as prescribed, usually once daily.,Do not take with allopurinol unless specifically instructed by your doctor, as it may increase side effects.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or jaundice immediately.,Avoid live vaccines (e.g., MMR, varicella) while on this medication.,Drink plenty of fluids to prevent kidney stones from uric acid accumulation.,If you miss a dose, do not double the next dose; take it as soon as remembered if within 12 hours of scheduled time.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PURINETHOL vs CLADRIBINE, answered by our medical review team.
PURINETHOL is a Antineoplastic Agent that works by Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PURINETHOL and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PURINETHOL is: 1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PURINETHOL and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PURINETHOL is classified as Category C. First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intraut. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.